Search Results - "tisagenlecleucel"

1

$Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia$

Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute...

by Shannon Cope, Dieter Ayers, Jie Zhang, Katharine Batt, Jeroen P. Jansen
Published 2019-09-01

Subjects: “...Tisagenlecleucel...”

Get full text

Article

2

$The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL$

The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL

by Forsberg MH, Das A, Saha K, Capitini CM
Published 2018-09-01

Subjects: “...tisagenlecleucel...”

Get full text

Article

3

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

by Michael M. Boyiadzis, Madhav V. Dhodapkar, Renier J. Brentjens, James N. Kochenderfer, Sattva S. Neelapu, Marcela V. Maus, David L. Porter, David G. Maloney, Stephan A. Grupp, Crystal L. Mackall, Carl H. June, Michael R. Bishop
Published 2018-12-01

Subjects: “...Tisagenlecleucel...”

Get full text

Article

4

$CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia$

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia

by Vairy S, Lopes Garcia J, Teira P, Bittencourt H
Published 2018-11-01

Subjects: “...Tisagenlecleucel...”

Get full text

Article

5

$Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain$

Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain

by Ribera Santasusana JM, de Andrés Saldaña A, García-Muñoz N, Gostkorzewicz J, Martínez Llinàs D, Díaz de Heredia C
Published 2020-05-01

Subjects: “...tisagenlecleucel...”

Get full text

Article

6

CAR-T Cell Therapies: An Overview of Clinical Studies Supporting Their Approved Use against Acute Lymphoblastic Leukemia and Large B-Cell Lymphomas

by Aamir Ahmad, Shahab Uddin, Martin Steinhoff
Published 2020-05-01

Subjects: “...tisagenlecleucel...”

Get full text

Article

7

Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review

by XiaoQin Wu, XinYue Zhang, RenDe Xun, MengSi Liu, Zhen Sun, JianChao Huang
Published 2021-07-01

Subjects: “...tisagenlecleucel...”

Get full text

Article

8

CARs on a highway with roadblocks

by Lorenzo Galluzzi, Peter Martin
Published 2017-12-01

Subjects: “...tisagenlecleucel...”

Get full text

Article

9

Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR

by Anita Badbaran, Carolina Berger, Kristoffer Riecken, Anne Kruchen, Maria Geffken, Ingo Müller, Nicolaus Kröger, Francis A. Ayuk, Boris Fehse
Published 2020-07-01

Subjects: “...tisagenlecleucel (tisa-cel, Kymriah)...”

Get full text

Article

10

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges

by Shinichi Makita, Katsuaki Imaizumi, Saiko Kurosawa, Kensei Tobinai
Published 2019-02-01

Subjects: “...tisagenlecleucel...”

Get full text

Article

11

Oligoclonal T Cells Transiently Expand and Express Tim-3 and PD-1 Following Anti-CD19 CAR T Cell Therapy: A Case Report

by Christopher Ronald Funk, Christopher T. Petersen, Neera Jagirdar, Sruthi Ravindranathan, David L. Jaye, Christopher R. Flowers, Amelia Langston, Edmund K. Waller
Published 2018-12-01

Subjects: “...tisagenlecleucel...”

Get full text

Article

12

$Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: A Pediatric Real World CAR Consortium Report$

Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: A Pediatric Real World CAR Consortium Report

by Baggott, C., Brown, P.A, Chinnabhandar, V., Curran, K.J, Egeler, E., Fabrizio, V.A, Hermiston, M., Karras, N.A, Keating, A.K, Krupski, C., Kunicki, M., Laetsch, T.W, Lane, A., Mackall, C.L, Margossian, S.P, Mavroukakis, S., Moskop, A., Myers, G.D, Pacenta, H., Phillips, C.L, Prabhu, S., Qayed, M., Rabik, C.A, Rossoff, J., Satwani, P., Schultz, L.M, Stefanski, H.E, Talano, J.-A, Verneris, M.R, Wilcox, R., Yasemin Goksenin, A.
Published 2022

Subjects: “...tisagenlecleucel T...”

View Fulltext in Publisher

Article

13

$Single-center experience using anakinra for steroid-refractory immune effector cell-Associated neurotoxicity syndrome (ICANS)$

Single-center experience using anakinra for steroid-refractory immune effector cell-Associated neurotoxicity syndrome (ICANS)

by Chen, Y.-B, Cook, D., Defilipp, Z., Dey, B., El-Jawahri, A.R, Frigault, M.J, Gallagher, K., Horick, N., Leick, M.B, Lindell, K., Maus, M.V, McAfee, S.L, O'Donnell, P., Spitzer, T., Trailor, M., Wehrli, M.
Published 2022

Subjects: “...tisagenlecleucel T...”

View Fulltext in Publisher

Article

Narrow Search